RxDoctor Payments Data

Edward Fisher, MD

Family Medicine · Frederick, MDNPI 1639153117

Payments from drug & device makers

$4,998in general payments, 2019–2025

Across 291 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$695
  • AbbVie$550
  • Lilly USA, LLC$523
  • Pfizer$374
  • Boehringer Ingelheim$301
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,992100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,998 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$144,721
Medicare patients
567
Services billed
1,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$164,104
EliquisApixaban58$64,571
MounjaroTirzepatide28$49,799
Tresiba Flextouch U-200Insulin Degludec24$29,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$28,912
JardianceEmpagliflozin25$27,239
Xigduo XrDapaglifloz Propaned/Metformin20$26,337
Synjardy XrEmpagliflozin/Metformin Hcl18$23,869
FarxigaDapagliflozin Propanediol15$19,511
CreonLipase/Protease/Amylase14$15,586
XareltoRivaroxaban11$12,036
Atorvastatin Calcium430$5,317
Rosuvastatin Calcium145$3,595
Testosterone11$3,413
Lisinopril296$2,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$695$164,104100 claims
PfizerEliquis$374$64,57158 claims
Boehringer IngelheimJardiance, Synjardy Xr$301$51,10843 claims
Lilly USA, LLCMounjaro$523$49,79928 claims
GSKTrelegy Ellipta$167$28,91228 claims
AstraZenecaFarxiga$1,100$19,51115 claims
AbbVieCreon, Synthroid$550$16,50133 claims
Johnson & JohnsonXarelto$19$12,03611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →